This study is for adults with a type of cancer called metastatic pancreatic ductal adenocarcinoma (mPDAC). "Metastatic" means the cancer has spread to other parts of the body. The study tests a new combination of drugs: TTX-030 and chemotherapy (gemcitabine + nab-paclitaxel), with or without an additional drug called budigalimab. It's a Phase 2 study, which means the drugs have been tested before, but researchers want to learn more about their safety and how well they work together. Participants will be randomly placed into one of three groups to receive different treatments.

To join, participants must be at least 18 years old, with a confirmed diagnosis of mPDAC, and not have received prior treatment for this cancer. They should be healthy enough for chemotherapy and not have allergies to study drugs.

Key Points:

• This is a randomized study with three different treatment groups.
• Participants must be ready for chemotherapy and meet specific health criteria.
• Discuss possible risks and benefits with your doctor before joining.